button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)

versus Standard of Care (SoC)
camrelizumab alone vs. Standard of Care (SoC) 1 certainty unassessablestatistically conclusive-27% certainty unassessable-29%-
nivolumab alone vs. Standard of Care (SoC) 1 certainty unassessablestatistically conclusive-21% certainty unassessable+8%-
pembrolizumab alone vs. Standard of Care (SoC) 1 certainty unassessable-10%--

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons